The global human papillomavirus therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The immunomodulators segment is expected to account for the largest share of the market in terms of revenue, followed by keratolytic agents and antineoplastic agents. The genital warts segment is expected to account for the largest share of the market in terms of volume, followed by genital cancer and epidermodysplasia verruciformis. North America is expected to account for the largest share of the global human papillomavirus therapeutics market in terms of revenue, followed by Europe and Asia Pacific. -There are more than 100 types of HPV, and about 40 of them can infect the genital area. -Some types of HPV can cause cervical cancer, and others can cause genital warts or anal cancer. -Infection with HPV is very common, with about 80% of people becoming infected at some point in their lives. -The Centers for Disease Control and Prevention (CDC) estimates that there are approximately 14 million new cases each year in the United States alone. -There are two vaccines available to prevent infection from certain types of HPV: Gardasil® and Cervarix®.
Industry Growth Insights published a new data on “Human Papillomaviru Therapeutics Market”. The research report is titled “Human Papillomaviru Therapeutics Market research by Types (Immunomodulators, Keratolytic Agents, Anti-neoplastic Agents, Sinecatechins), By Applications (Genital Warts, Genital Cancer, Epidermodysplasia Verruciformis, Oral Papillomas, Oropharyngeal Cancer, Laryngeal Papillomatosis, Others), By Players/Companies AbbVie, Actavis, Clinigen Group, Merck, Perrigo Company, Roche, Valeant Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Papillomaviru Therapeutics Market Research Report
By Type
Immunomodulators, Keratolytic Agents, Anti-neoplastic Agents, Sinecatechins
By Application
Genital Warts, Genital Cancer, Epidermodysplasia Verruciformis, Oral Papillomas, Oropharyngeal Cancer, Laryngeal Papillomatosis, Others
By Companies
AbbVie, Actavis, Clinigen Group, Merck, Perrigo Company, Roche, Valeant Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Human Papillomaviru Therapeutics Market Report Segments:
The global Human Papillomaviru Therapeutics market is segmented on the basis of:
Types
Immunomodulators, Keratolytic Agents, Anti-neoplastic Agents, Sinecatechins
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Genital Warts, Genital Cancer, Epidermodysplasia Verruciformis, Oral Papillomas, Oropharyngeal Cancer, Laryngeal Papillomatosis, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Actavis
- Clinigen Group
- Merck
- Perrigo Company
- Roche
- Valeant Pharmaceuticals
Highlights of The Human Papillomaviru Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunomodulators
- Keratolytic Agents
- Anti-neoplastic Agents
- Sinecatechins
- By Application:
- Genital Warts
- Genital Cancer
- Epidermodysplasia Verruciformis
- Oral Papillomas
- Oropharyngeal Cancer
- Laryngeal Papillomatosis
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Papillomaviru Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human Papillomavirus (HPV) is a virus that can cause cervical cancer. HPV vaccines are available to help protect people from getting HPV infections and developing cervical cancer.
Some of the key players operating in the human papillomaviru therapeutics market are AbbVie, Actavis, Clinigen Group, Merck, Perrigo Company, Roche, Valeant Pharmaceuticals.
The human papillomaviru therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Papillomaviru Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Papillomaviru Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Papillomaviru Therapeutics Market - Supply Chain
4.5. Global Human Papillomaviru Therapeutics Market Forecast
4.5.1. Human Papillomaviru Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Papillomaviru Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Papillomaviru Therapeutics Market Absolute $ Opportunity
5. Global Human Papillomaviru Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Papillomaviru Therapeutics Market Size and Volume Forecast by Type
5.3.1. Immunomodulators
5.3.2. Keratolytic Agents
5.3.3. Anti-neoplastic Agents
5.3.4. Sinecatechins
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Papillomaviru Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Papillomaviru Therapeutics Market Size and Volume Forecast by Application
6.3.1. Genital Warts
6.3.2. Genital Cancer
6.3.3. Epidermodysplasia Verruciformis
6.3.4. Oral Papillomas
6.3.5. Oropharyngeal Cancer
6.3.6. Laryngeal Papillomatosis
6.3.7. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Papillomaviru Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Papillomaviru Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Papillomaviru Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Papillomaviru Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Papillomaviru Therapeutics Demand Share Forecast, 2019-2026
9. North America Human Papillomaviru Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Papillomaviru Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Papillomaviru Therapeutics Market Size and Volume Forecast by Application
9.4.1. Genital Warts
9.4.2. Genital Cancer
9.4.3. Epidermodysplasia Verruciformis
9.4.4. Oral Papillomas
9.4.5. Oropharyngeal Cancer
9.4.6. Laryngeal Papillomatosis
9.4.7. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Papillomaviru Therapeutics Market Size and Volume Forecast by Type
9.7.1. Immunomodulators
9.7.2. Keratolytic Agents
9.7.3. Anti-neoplastic Agents
9.7.4. Sinecatechins
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Papillomaviru Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Human Papillomaviru Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Papillomaviru Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Papillomaviru Therapeutics Market Size and Volume Forecast by Application
10.4.1. Genital Warts
10.4.2. Genital Cancer
10.4.3. Epidermodysplasia Verruciformis
10.4.4. Oral Papillomas
10.4.5. Oropharyngeal Cancer
10.4.6. Laryngeal Papillomatosis
10.4.7. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Papillomaviru Therapeutics Market Size and Volume Forecast by Type
10.7.1. Immunomodulators
10.7.2. Keratolytic Agents
10.7.3. Anti-neoplastic Agents
10.7.4. Sinecatechins
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Papillomaviru Therapeutics Demand Share Forecast, 2019-2026
11. Europe Human Papillomaviru Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Papillomaviru Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Papillomaviru Therapeutics Market Size and Volume Forecast by Application
11.4.1. Genital Warts
11.4.2. Genital Cancer
11.4.3. Epidermodysplasia Verruciformis
11.4.4. Oral Papillomas
11.4.5. Oropharyngeal Cancer
11.4.6. Laryngeal Papillomatosis
11.4.7. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Papillomaviru Therapeutics Market Size and Volume Forecast by Type
11.7.1. Immunomodulators
11.7.2. Keratolytic Agents
11.7.3. Anti-neoplastic Agents
11.7.4. Sinecatechins
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Papillomaviru Therapeutics Demand Share, 2019-2026
12. Asia Pacific Human Papillomaviru Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Papillomaviru Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Papillomaviru Therapeutics Market Size and Volume Forecast by Application
12.4.1. Genital Warts
12.4.2. Genital Cancer
12.4.3. Epidermodysplasia Verruciformis
12.4.4. Oral Papillomas
12.4.5. Oropharyngeal Cancer
12.4.6. Laryngeal Papillomatosis
12.4.7. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Papillomaviru Therapeutics Market Size and Volume Forecast by Type
12.7.1. Immunomodulators
12.7.2. Keratolytic Agents
12.7.3. Anti-neoplastic Agents
12.7.4. Sinecatechins
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Papillomaviru Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Human Papillomaviru Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Papillomaviru Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Papillomaviru Therapeutics Market Size and Volume Forecast by Application
13.4.1. Genital Warts
13.4.2. Genital Cancer
13.4.3. Epidermodysplasia Verruciformis
13.4.4. Oral Papillomas
13.4.5. Oropharyngeal Cancer
13.4.6. Laryngeal Papillomatosis
13.4.7. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Papillomaviru Therapeutics Market Size and Volume Forecast by Type
13.7.1. Immunomodulators
13.7.2. Keratolytic Agents
13.7.3. Anti-neoplastic Agents
13.7.4. Sinecatechins
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Papillomaviru Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Papillomaviru Therapeutics Market: Market Share Analysis
14.2. Human Papillomaviru Therapeutics Distributors and Customers
14.3. Human Papillomaviru Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AbbVie
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Actavis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Clinigen Group
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Perrigo Company
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Roche
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Valeant Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook